que se leu este artigo
array:25 [ "pii" => "S2255553617300794" "issn" => "22555536" "doi" => "10.1016/j.jpedp.2017.07.002" "estado" => "S300" "fechaPublicacion" => "2017-11-01" "aid" => "512" "copyright" => "Sociedade Brasileira de Pediatria" "copyrightAnyo" => "2017" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "J Pediatr (Rio J). 2017;93:639-48" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 914 "formatos" => array:3 [ "EPUB" => 91 "HTML" => 594 "PDF" => 229 ] ] "Traduccion" => array:1 [ "en" => array:20 [ "pii" => "S0021755717306344" "issn" => "00217557" "doi" => "10.1016/j.jped.2017.03.005" "estado" => "S300" "fechaPublicacion" => "2017-11-01" "aid" => "512" "copyright" => "Sociedade Brasileira de Pediatria" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "J Pediatr (Rio J). 2017;93:639-48" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 708 "formatos" => array:3 [ "EPUB" => 84 "HTML" => 347 "PDF" => 277 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Variants in the interleukin 8 gene and the response to inhaled bronchodilators in cystic fibrosis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "639" "paginaFinal" => "648" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Variantes no gene da interleucina 8 e a resposta a broncodilatadores inalatórios na fibrose cística" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 4239 "Ancho" => 3284 "Tamanyo" => 641459 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Association of rs4073 and rs2227306 variants of <span class="elsevierStyleItalic">IL-8</span> (interleukin-8) with the response to inhaled bronchodilators in cystic fibrosis patients. (A) Association between forced expiratory volume in 1<span class="elsevierStyleHsp" style=""></span>s (FEV<span class="elsevierStyleInf">1</span>) of forced vital capacity (FVC) and rs4073, dominant model and two identified mutations in the <span class="elsevierStyleItalic">CFTR</span> gene (cystic fibrosis transmembrane regulator) belonging to classes I, II, and/or III (<span class="elsevierStyleItalic">CFTR-B</span> group) (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.028; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.112). (AA<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>AT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>39; mean of 4.77<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>8.95; median of 4 (ranging from −9 to 48). (TT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>21; mean of −0.86<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>5.42; median of −1 (ranging from −6 to 15). (B) Association of FEV<span class="elsevierStyleInf">1</span>/FVC ratio with rs4073, over-dominant model and <span class="elsevierStyleItalic">CFTR-B</span> group (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.029; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.116). (AA<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>TT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>30; mean of 1.17<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>7.36; median of 0 (ranging from −12 to 23). (AT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>29; mean of 4.76<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>7.58; median of 4 (ranging from −9 to 32). (C) Association of forced expiratory flow of 50% (FEF<span class="elsevierStyleInf">50%</span>) of FVC with rs4073, dominant model, and <span class="elsevierStyleItalic">CFTR-B</span> group (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.046; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.184). (AA<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>AT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>37; mean of 17.38<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>24.18; median of 16 (ranging from −20 to 89). (TT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>21; mean of 4.95<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>20.8; median of −2 (ranging from −19 to 55). (D) Association of FEF<span class="elsevierStyleInf">50%</span> with rs2227306, dominant model, and <span class="elsevierStyleItalic">CFTR-B</span> group (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.05; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.083). (CC) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>15; mean of 1.47<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>17.22; median of 0 (ranging from −20 to 29). (CT<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>TT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>44; mean of 15.84<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>25.04; median of 10.5 (ranging from −28 to 89). (E) Association of FEF<span class="elsevierStyleInf">50%</span> with rs2227306, over-dominant model, and <span class="elsevierStyleItalic">CFTR-B</span> group (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.033; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.083). (CC<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>TT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>33; mean of 6.06<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>20.27; median of 4 (ranging from −20 to 55). (CT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>23; mean of 19.96<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>26.43; median of 19 (ranging from −28 to 89). (F) Association of forced expiratory flow of 75% (FEF<span class="elsevierStyleInf">75%</span>) of FVC with rs4073, co-dominant model regardless of identified mutations in the <span class="elsevierStyleItalic">CFTR</span> gene (<span class="elsevierStyleItalic">CFTR-A</span> group) (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.044; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.058). 1<span class="elsevierStyleHsp" style=""></span>≠<span class="elsevierStyleHsp" style=""></span>3. (AA) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>28; mean of 29.93<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>39.98; median of 30 (ranging from −47 to 142). (AT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>42; mean of 24.81<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>53.57; median of 14 (ranging from −58 to 235). (TT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>28; mean of 9.14<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>36.95; median of 2.5 (ranging from −35 to 119). (G) Association of FEF<span class="elsevierStyleInf">75%</span> with rs4073, dominant model, and <span class="elsevierStyleItalic">CFTR-B</span> group (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.024; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.096). (AA<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>AT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>38; mean of 33<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>55.23; median of 16 (ranging from −27 to 235). (TT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>21; mean of 5.43<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>35.93; median of 2 (ranging from −35 to 119). (H) Association of FEF<span class="elsevierStyleInf">75%</span> with rs4073, dominant model, and <span class="elsevierStyleItalic">CFTR-A</span> group (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.034; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.058). (AA<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>AT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>70; mean of 26.86<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>48.34; median of 18 (ranging from −58 to 235). (TT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>28; mean of 9.14<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>36.95; median of 2.5 (ranging from −35 to 119). (I) Association of FEF<span class="elsevierStyleInf">75%</span> with rs4073, recessive model, and <span class="elsevierStyleItalic">CFTR-A</span> group (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.04; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.058). (AA) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>28; mean of 29.93<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>39.98; median of 30 (ranging from −47 to 142). (AT<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>TT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>70; mean of 18.54<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>47.95; median of 10 (ranging from −58 to 235). (J) Association of FEF between 25% and 75% (FEF<span class="elsevierStyleInf">25–75%</span>) of FVC with rs4073, co-dominant model and <span class="elsevierStyleItalic">CFTR-B</span> group (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.012; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.024). TT<span class="elsevierStyleHsp" style=""></span>≠<span class="elsevierStyleHsp" style=""></span>AA and AT. (AA) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>9; mean of 25.78<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>23.14; median of 30 (ranging from −21 to 57). (AT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>29; mean of 18.38<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>29.04; median of 14 (ranging from −33 to 117). (TT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>21; mean of 2.14<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>23.74; median of 0 (ranging from −51 to 65). (K) Association of FEF<span class="elsevierStyleInf">25–75%</span> with rs4073, dominant model, and <span class="elsevierStyleItalic">CFTR-B</span> group (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.007; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.024). (AA<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>ATT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>38; mean of 20.13<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>27.64; median of 18.5 (ranging from −33 to 117). (TT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>23; mean of 2.14<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>23.74; median of 0 (ranging from −51 to 65). (L) Association of FEF<span class="elsevierStyleInf">25–75%</span> with rs4073, dominant model, and <span class="elsevierStyleItalic">CFTR-A</span> group (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.029; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.1). (AA<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>AT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>82; mean of 15.48<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>27.2; median of 15 (ranging from −40 to 117). (TT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>33; mean of 5.94<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>27.33; median of 0 (ranging from −51 to 76). (M) Association of FEF<span class="elsevierStyleInf">25–75%</span> with rs4073, recessive model, and <span class="elsevierStyleItalic">CFTR-B</span> group (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.047; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.063). (AA) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>9; mean of 25.78<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>23.14; median of 30 (ranging from −21 to 57). (AT<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>TT) <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>50; mean of 11.56<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>27.89; median of 8 (ranging from −51 to 117). The dot corresponds to median values and the bar corresponds to the 95% confidence interval.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Larissa Lazzarini Furlan, José Dirceu Ribeiro, Carmen Sílvia Bertuzzo, João Batista Salomão Junior, Dorotéia Rossi Silva Souza, Fernando Augusto Lima Marson" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Larissa Lazzarini" "apellidos" => "Furlan" ] 1 => array:2 [ "nombre" => "José Dirceu" "apellidos" => "Ribeiro" ] 2 => array:2 [ "nombre" => "Carmen Sílvia" "apellidos" => "Bertuzzo" ] 3 => array:2 [ "nombre" => "João Batista" "apellidos" => "Salomão Junior" ] 4 => array:2 [ "nombre" => "Dorotéia Rossi Silva" "apellidos" => "Souza" ] 5 => array:2 [ "nombre" => "Fernando Augusto Lima" "apellidos" => "Marson" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "pt" => array:9 [ "pii" => "S2255553617300794" "doi" => "10.1016/j.jpedp.2017.07.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "pt" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2255553617300794?idApp=UINPBA000049" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0021755717306344?idApp=UINPBA000049" "url" => "/00217557/0000009300000006/v1_201711050042/S0021755717306344/v1_201711050042/en/main.assets" ] ] "itemSiguiente" => array:20 [ "pii" => "S2255553617300824" "issn" => "22555536" "doi" => "10.1016/j.jpedp.2017.08.001" "estado" => "S300" "fechaPublicacion" => "2017-11-01" "aid" => "515" "copyright" => "Sociedade Brasileira de Pediatria" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "J Pediatr (Rio J). 2017;93:649-54" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1102 "formatos" => array:3 [ "EPUB" => 105 "HTML" => 716 "PDF" => 281 ] ] "pt" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Artigo Original</span>" "titulo" => "Neonatal screening: 9% of children with filter paper thyroid‐stimulating hormone levels between 5 and 10 μIU/mL have congenital hypothyroidism" "tienePdf" => "pt" "tieneTextoCompleto" => "pt" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "649" "paginaFinal" => "654" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Triagem neonatal: 9% das crianças com TSH em papel filtro entre 5 e 10<span class="elsevierStyleHsp" style=""></span>μUI/mL têm hipotireoidismo congênito" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "pt" => true ] "contienePdf" => array:1 [ "pt" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1189 "Ancho" => 1667 "Tamanyo" => 92256 ] ] "descripcion" => array:1 [ "pt" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Fluxograma da triagem para hipotireoidismo congênito de abril de 2003 a setembro de 2009.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Flávia C. Christensen‐Adad, Carolina T. Mendes‐dos‐Santos, Maura M.F. Goto, Letícia E. Sewaybricker, Lília F.R. D'Souza‐Li, Gil Guerra‐Junior, André M. Morcillo, Sofia Helena V. Lemos‐Marini" "autores" => array:8 [ 0 => array:2 [ "nombre" => "Flávia C." "apellidos" => "Christensen‐Adad" ] 1 => array:2 [ "nombre" => "Carolina T." "apellidos" => "Mendes‐dos‐Santos" ] 2 => array:2 [ "nombre" => "Maura M.F." "apellidos" => "Goto" ] 3 => array:2 [ "nombre" => "Letícia E." "apellidos" => "Sewaybricker" ] 4 => array:2 [ "nombre" => "Lília F.R." "apellidos" => "D'Souza‐Li" ] 5 => array:2 [ "nombre" => "Gil" "apellidos" => "Guerra‐Junior" ] 6 => array:2 [ "nombre" => "André M." "apellidos" => "Morcillo" ] 7 => array:2 [ "nombre" => "Sofia Helena V." "apellidos" => "Lemos‐Marini" ] ] ] ] ] "idiomaDefecto" => "pt" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S002175571630170X" "doi" => "10.1016/j.jped.2017.05.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S002175571630170X?idApp=UINPBA000049" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2255553617300824?idApp=UINPBA000049" "url" => "/22555536/0000009300000006/v1_201711030110/S2255553617300824/v1_201711030110/pt/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S2255553617300678" "issn" => "22555536" "doi" => "10.1016/j.jpedp.2017.06.006" "estado" => "S300" "fechaPublicacion" => "2017-11-01" "aid" => "509" "copyright" => "Sociedade Brasileira de Pediatria" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "J Pediatr (Rio J). 2017;93:632-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1803 "formatos" => array:3 [ "EPUB" => 90 "HTML" => 1360 "PDF" => 353 ] ] "pt" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Artigo Original</span>" "titulo" => "Do infants with cow's milk protein allergy have inadequate levels of vitamin D?" "tienePdf" => "pt" "tieneTextoCompleto" => "pt" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "632" "paginaFinal" => "638" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Lactentes com alergia à proteína do leite de vaca apresentam níveis inadequados de vitamina D?" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "pt" => true ] "contienePdf" => array:1 [ "pt" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1546 "Ancho" => 2102 "Tamanyo" => 83893 ] ] "descripcion" => array:1 [ "pt" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Frequências dos graus de suficiência da vitamina D nos lactentes com APLV e no grupo controle, atendidos ambulatorialmente em hospital universitário, Recife–PE (2013–2015).</p> <p id="spar0050" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">a</span> Teste exato de Fisher.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Cristiane M. Silva, Silvia A. da Silva, Margarida M. de C. Antunes, Gisélia Alves Pontes da Silva, Emanuel Sávio Cavalcanti Sarinho, Katia G. Brandt" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Cristiane M." "apellidos" => "Silva" ] 1 => array:2 [ "nombre" => "Silvia A. da" "apellidos" => "Silva" ] 2 => array:2 [ "nombre" => "Margarida M. de C." "apellidos" => "Antunes" ] 3 => array:2 [ "nombre" => "Gisélia Alves Pontes da" "apellidos" => "Silva" ] 4 => array:2 [ "nombre" => "Emanuel Sávio Cavalcanti" "apellidos" => "Sarinho" ] 5 => array:2 [ "nombre" => "Katia G." "apellidos" => "Brandt" ] ] ] ] ] "idiomaDefecto" => "pt" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S0021755717305247" "doi" => "10.1016/j.jped.2017.01.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0021755717305247?idApp=UINPBA000049" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2255553617300678?idApp=UINPBA000049" "url" => "/22555536/0000009300000006/v1_201711030110/S2255553617300678/v1_201711030110/pt/main.assets" ] "pt" => array:21 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Artigo Original</span>" "titulo" => "Variants in the interleukin 8 gene and the response to inhaled bronchodilators in cystic fibrosis" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "639" "paginaFinal" => "648" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Larissa Lazzarini Furlan, José Dirceu Ribeiro, Carmen Sílvia Bertuzzo, João Batista Salomão Junior, Dorotéia Rossi Silva Souza, Fernando Augusto Lima Marson" "autores" => array:6 [ 0 => array:3 [ "nombre" => "Larissa Lazzarini" "apellidos" => "Furlan" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 1 => array:3 [ "nombre" => "José Dirceu" "apellidos" => "Ribeiro" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Carmen Sílvia" "apellidos" => "Bertuzzo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "João Batista" "apellidos" => "Salomão Junior" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] 4 => array:3 [ "nombre" => "Dorotéia Rossi Silva" "apellidos" => "Souza" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] ] ] 5 => array:4 [ "nombre" => "Fernando Augusto Lima" "apellidos" => "Marson" "email" => array:1 [ 0 => "fernandolimamarson@hotmail.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:6 [ 0 => array:3 [ "entidad" => "Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, SP, Brasil" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Universidade Estadual de Campinas (Unicamp), Faculdade de Ciências Médicas, Departamento de Pediatria, Campinas, SP, Brasil" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Universidade Estadual de Campinas (Unicamp), Faculdade de Ciências Médicas, Departamento de Genética Médica, Campinas, SP, Brasil" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Faculdade de Medicina de São José do Rio Preto, Hospital Universitário, Departamento de Pediatria, São José do Rio Preto, SP, Brasil" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Faculdade de Medicina de São José do Rio Preto, Hospital Universitário, Departamento de Pneumologia Pediátrica, São José do Rio Preto, SP, Brasil" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Faculdade de Medicina de São José do Rio Preto, Centro de Pesquisa de Bioquímica e Biologia Molecular, Departamento de Biologia Molecular, São José do Rio Preto, SP, Brasil" "etiqueta" => "f" "identificador" => "aff0030" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Autor para correspondência." ] ] ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Variantes no gene da interleucina 8 e a resposta a broncodilatadores inalatórios na fibrose cística" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 4239 "Ancho" => 3276 "Tamanyo" => 668369 ] ] "descripcion" => array:1 [ "pt" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Associação das variantes rs4073 e rs2227306 da <span class="elsevierStyleItalic">IL‐8</span> (interleucina‐8) à resposta a broncodilatadores inalatórios em pacientes com fibrose cística. A. Associação entre o volume expiratório forçado no 1° segundo (VEF<span class="elsevierStyleInf">1</span>) da capacidade vital forçada (CVF) e rs4073, modelo dominante e duas mutações identificadas no gene do <span class="elsevierStyleItalic">RTFC</span> (regulador da condutância transmembrana da fibrose cística) pertencente às classes I, II e/ou III (grupo <span class="elsevierStyleItalic">RTFC</span>‐B) (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,028; p<span class="elsevierStyleSup">c</span>–0,112). (AA +<span class="elsevierStyleHsp" style=""></span>AT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>39; média de 4,77<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>8,95; mediana de 4 (variação de −9 a 48). (TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>21; média de 0,86<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>5,42; mediana de −1 (variação de −6 a 15). B. Associação da proporção VEF1/CVF à variante rs4073, modelo superdominante e grupo <span class="elsevierStyleItalic">RTFC</span>‐B (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,029; pc<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,116). (TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>30; média de 0,86<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>7,36; mediana de 0 (variação de −12 a 23). (AT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>29; média de 4,76<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>7,58; mediana de 4 (variação de −9 a 32). C. Associação do fluxo expiratório forçado de 50% (FEF<span class="elsevierStyleInf">50%</span>) da CVF à variante rs4073, modelo dominante e grupo <span class="elsevierStyleItalic">RTFC</span>‐B (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,046; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,184). (AA<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>AT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>37; média de 17,38<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>24,18; mediana de 16 (variação de −20 a 89). (TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>21; média de 4,95<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>20,80; mediana de −2 (variação de −19 a 55). D. Associação do FEF<span class="elsevierStyleInf">50%</span> à variante rs2227306, modelo dominante e grupo <span class="elsevierStyleItalic">RTFC‐B</span> (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,050; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,083). (CC) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>15; média de 1,47<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>17,22; mediana de 0 (variação de −20 a 29). (CT<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>44; média de 15,84<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>25,04; mediana de 10,50 (variação de −28 a 89). E. Associação do FEF<span class="elsevierStyleInf">50%</span> à variante rs2227306, modelo superdominante e grupo <span class="elsevierStyleItalic">RTFC</span>‐B (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,033; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,083). (CC<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>33; média de 6,06<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>20,27; mediana de 4 (variação de −20 a 55). (CT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>23; média de 19,96<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>26,43; mediana de 19 (variação de −28 a 89). F. Associação do fluxo expiratório forçado de 75% (FEF<span class="elsevierStyleInf">75%</span>) da CVF à variante rs4073, modelo codominante independentemente das mutações identificadas no gene do <span class="elsevierStyleItalic">RTFC</span> (grupo RTFC‐A) (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,044; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,058). 1 ≠ 3. (AA) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>28; média de 29,93<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>39,98; mediana de 30 (variação de −47 a 142). (AT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>42; média de 24,81<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>53,57; mediana de 14 (variação de −58 a 235). (TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>28; média de 9,14<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>36,95; mediana de 2,5 (variação de −35 a 119). G. Associação do FEF<span class="elsevierStyleInf">75%</span> à variante rs4073, modelo dominante e grupo <span class="elsevierStyleItalic">RTFC</span>‐B (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,024; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,096). (AA<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>AT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>38; média de 33<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>55,23; mediana de (variação de −27 a 235). (TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>21; média de 5,43<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>35,93; mediana de 2 (variação de −35 a 119). H. Associação do FEF<span class="elsevierStyleInf">75%</span> à variante rs4073, modelo dominante e grupo <span class="elsevierStyleItalic">RTFC‐A</span> (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,034; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,058). (AA<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>AT) (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>70; média de 26,86<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>48,34; mediana de 18 (variação de −58 a 235). (TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>28; média de 9,14<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>36,95; mediana de 2,5 (variação de −35 a 119). I. Associação do FEF<span class="elsevierStyleInf">75%</span> à variante rs4073, modelo recessivo e grupo <span class="elsevierStyleItalic">RTFC‐A</span> (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,040; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,058). (AA) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>28; média de 29,93<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>39,98; mediana de 30 (variação de −47 a 142). (AT<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>70; média de 18,54<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>47,95; mediana de 10 (variação de −58 a 235). J. Associação do FEF entre 25 e 75% (FEF<span class="elsevierStyleInf">25‐75%</span>) da CVF à variante rs4073, modelo codominante e grupo <span class="elsevierStyleItalic">RTFC‐B</span> (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,012; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,024). TT ≠ AA e AT. (AA) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>9; média de 25,78<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>23,14; mediana de 30 (variação de −21 a 57). (AT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>29; média de 18,38<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>29,04; mediana de 14 (variação de −33 a 117). (TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>21; média de 2,14<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>23,74; mediana de 0 (variação de −51 a 65). K. Associação do FEF<span class="elsevierStyleInf">25‐75%</span> à variante rs4073, modelo dominante e grupo <span class="elsevierStyleItalic">RTFC‐B</span> (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,007; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,024). (AA<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>ATT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>38; média de 20,13<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>27,64; mediana de 18,50 (variação de −33 a 117). (TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>23; média de 2,14<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>23,74; mediana de 0 (variação de −51 a 65). L. Associação do FEF<span class="elsevierStyleInf">25‐75%</span> à variante rs4073, modelo dominante e grupo <span class="elsevierStyleItalic">RTFC‐A</span> (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,029; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,100). (AA<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>AT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>82; média de 15,48<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>27,20; mediana de 15 (variação de −40 a 117). (TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>33; média de 5,94<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>27,33; mediana de 0 (variação de −51 a 76). M. Associação do FEF<span class="elsevierStyleInf">25‐75%</span> à variante rs4073, modelo recessivo e grupo <span class="elsevierStyleItalic">RTFC‐B</span> (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,047; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,063). (AA) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>9; média de 25,78<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>23,14; mediana de 30 (variação de −21 a 57). (AT<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>50; média de 11,56<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>27,89; mediana de 8 (variação de −51 a 117). O ponto corresponde aos valores medianos e a barra corresponde a intervalo de confiança de 95%.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Introdução</span><p id="par0005" class="elsevierStylePara elsevierViewall">A resposta a broncodilatadores inalatórios (BD) na fibrose cística (FC) (OMIM: n° 219700) é muito variável e depende do genótipo do <span class="elsevierStyleItalic">RTFC</span> (Regulador da Condutância Transmembrana da Fibrose Cística), dos sintomas pulmonares e, principalmente, de variantes nos genes modificadores, como o Receptor Adrenérgico Beta 2 (<span class="elsevierStyleItalic">ADRB2</span>).<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">1</span></a> Até agora, apenas alguns estudos investigaram essa resposta.</p><p id="par0010" class="elsevierStylePara elsevierViewall">As mutações no gene do <span class="elsevierStyleItalic">RTFC</span> causam FC, devido a deficiência, disfunção ou ausência da proteína do <span class="elsevierStyleItalic">RTFC</span>.<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">2</span></a> A FC é caracterizada por um ciclo contínuo de inflamação crônica das vias aéreas, que pode ser exacerbada pela interleucina 8 (<span class="elsevierStyleItalic">IL‐8</span>), um importante mediador pró‐inflamatório. A <span class="elsevierStyleItalic">IL‐8</span> é responsável por iniciar e aumentar a resposta provocadora na presença de patógenos específicos, causa ativação e migração de neutrófilos do sangue periférico para os tecidos.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">3</span></a> A inflamação crônica das vias aéreas é o caminho comum final de lesão pulmonar. Ela é responsável pelo aumento na permeabilidade vascular, contribui para edema intersticial, alveolar e das vias aéreas.</p><p id="par0015" class="elsevierStylePara elsevierViewall">O tratamento da doença pulmonar na FC inclui anti‐inflamatórios, corticosteroides inalatórios, antibióticos, mucolítico, solução salina hipertônica e fisioterapia. Dentre as possíveis terapias, há pouca comprovação que corrobore um papel dos BD na FC.<a class="elsevierStyleCrossRefs" href="#bib0170"><span class="elsevierStyleSup">4,5</span></a> Contudo, os BD normalmente são prescritos por um tempo maior devido a episódios de pieira e dispneia na FC.<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">6</span></a> Os BD reduzem a liberação de mediadores, responsáveis pelo recrutamento e pela ativação de células inflamatórias, ativam a neurotransmissão colinérgica, e por melhorar a permeabilidade vascular. Eles também aumentam o transporte mucociliar, levam à redução da inflamação pulmonar.<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">7</span></a> A resposta a BD depende, em parte, da proteína do <span class="elsevierStyleItalic">RTFC</span>, que interage com a proteína do ADRB2 para promover broncodilatação.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">8</span></a> A espirometria é o principal método de avaliar a função pulmonar, a gravidade e a progressão da doença, bem como a resposta a BD.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Inflamação neutrofílica intensa e baixa hiperreactividade brônquica são características comumente observadas na FC.<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">9</span></a> Ademais, a resposta das variantes genéticas aos BD é pouco conhecida.<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">1</span></a> Pode‐se destacar o papel da <span class="elsevierStyleItalic">IL‐8</span> no componente neutrofílico da doença pulmonar na FC. Os genes que podem estar associados à gravidade da FC e possivelmente à resposta a BD foram relatados aqui e na literatura científica de todo o mundo.<a class="elsevierStyleCrossRefs" href="#bib0155"><span class="elsevierStyleSup">1,10–12</span></a> O gene da <span class="elsevierStyleItalic">IL‐8</span> deve ser destacado, pois ele tem influência direta sobre a inflamação pulmonar e pode ser eficaz na resposta a BD. Portanto, este estudo comparou as variantes genéticas da <span class="elsevierStyleItalic">IL‐8</span> rs4073, rs2227306 e rs2227307 com a resposta a BD em pacientes com FC, com o uso da espirometria.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Material e métodos</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Pacientes</span><p id="par0025" class="elsevierStylePara elsevierViewall">Foi conduzido um estudo transversal com 186 pacientes com FC, selecionados em dois centros universitários de referência (Faculdade de Medicina de São José do Rio Preto e Universidade de Campinas) para tratamento de FC, de 2013 a 2015. O estudo foi aprovado pelo Comitê de Ética em Pesquisa da Universidade Estadual de Campinas, São Paulo, Brasil (n° 528/2008). Todos os participantes foram informados sobre o estudo e assinaram o Documento de Consentimento Informado. Para os pacientes com menos de 18 anos, o Consentimento Informado foi assinado pelo pai/mãe ou guardião. O estudo seguiu as recomendações da Declaração de Helsinque.</p><p id="par0030" class="elsevierStylePara elsevierViewall">O diagnóstico de FC foi confirmado pela presença de duas concentrações alteradas de sódio e cloreto no suor (nível de cloreto acima de 60 mEq/L). Além disso, nenhum paciente foi submetido a teste inicial de tripsinogênio imunorreativo (IRT). Em um grupo de 91 pacientes, houve duas mutações no gene do <span class="elsevierStyleItalic">RTFC</span> pertencentes às classes I, II e/ou III (associadas à maior gravidade da doença, devido à ausência ou não funcionalidade da proteína do <span class="elsevierStyleItalic">RTFC</span>);<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">13</span></a> 60 pacientes não apresentaram mutação identificada do gene do <span class="elsevierStyleItalic">RTFC</span> ou apresentaram duas mutações que pertencem às classes IV, V ou VI; e 35 pacientes apresentaram uma mutação no gene do <span class="elsevierStyleItalic">RTFC</span> que pertence às classes I, II ou III e uma mutação não identificada ou pertencente às classes IV, V ou VI (<a class="elsevierStyleCrossRef" href="#tbl0005">tabela 1</a>).</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Variáveis clínicas</span><p id="par0035" class="elsevierStylePara elsevierViewall">As seguintes variáveis foram analisadas: escores clínicos (Shwachman‐Kulczycki, Kanga e Bhalla); índice de massa corporal (IMC) de pacientes com mais de 18 anos, com a fórmula IMC<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>peso/altura;<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">2</span></a> a versão 3.0.1 do programa Anthro (Organização Mundial de Saúde [OMS], 2006) foi usada para crianças com menos de cinco anos e a versão 1.0.2 do programa Anthro Plus (Organização Mundial de Saúde [OMS], 2007) foi usada para crianças de cinco anos a adolescentes de 18 anos; idade do paciente e idade na época do diagnóstico; primeiro sintoma clínico (um sintoma geral, sintomas pulmonares e digestivos); período até a primeira colonização por <span class="elsevierStyleItalic">Pseudomonas aeruginosa</span> mucoide (PAM); microrganismos identificados na cultura de escarro de rotina (<span class="elsevierStyleItalic">P. aeruginosa</span>, <span class="elsevierStyleItalic">Achromobacter xylosoxidans</span>, <span class="elsevierStyleItalic">Burkolderia cepacia</span> e <span class="elsevierStyleItalic">Staphylococcus aureus</span> mucoides e não mucoides); saturação de oxigênio no sangue arterial transcutânea (SaO<span class="elsevierStyleInf">2</span>); espirometria e comorbidades (pólipos nasais, osteoporose, íleo meconial, <span class="elsevierStyleItalic">diabetes mellitus</span> e insuficiência pancreática).</p><p id="par0040" class="elsevierStylePara elsevierViewall">A espirometria foi feita em pacientes com mais de sete anos, com o espirômetro CPFS/D (MedGraphics, Saint Paul, Minnesota, EUA). Os dados foram registrados pela versão 3.8B do <span class="elsevierStyleItalic">software</span> PF BREEZE para Windows 95/98/NT (American Thoracic Society) e avaliados em percentagem de valores preditivos para: capacidade vital forçada (% de CVF), volume expiratório forçado no 1° segundo da CVF (VEF<span class="elsevierStyleInf">1</span>), proporção VEF<span class="elsevierStyleInf">1</span>/CVF, fluxo expiratório forçado a 25% da CVF (FEF<span class="elsevierStyleInf">25%</span>), fluxo expiratório forçado a 50% da CVF (FEF<span class="elsevierStyleInf">50%</span>), fluxo expiratório forçado a 75% da CVF (FEF<span class="elsevierStyleInf">75%</span>), fluxo expiratório forçado entre 25% e 75% da CVF (FEF<span class="elsevierStyleInf">25‐75%</span>), fluxo expiratório forçado máximo (FEF<span class="elsevierStyleInf">max</span>) e volume de reserva expiratória (VRE). Os dados da espirometria são mostrados em percentual do valor preditivo de acordo com as equações de Polgar e Promadhat (1971); Pereira et al. (2007) e Duarte et al. (2007).<a class="elsevierStyleCrossRefs" href="#bib0220"><span class="elsevierStyleSup">14–16</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">Todos os pacientes submetidos a espirometria fizeram o teste antes e 15 minutos após administração dos BD [albutrol–C<span class="elsevierStyleInf">13</span>H<span class="elsevierStyleInf">21</span>NO<span class="elsevierStyleInf">3</span> (400 mg)]. Os pacientes em terapia com BD foram orientados a interromper a medicação oito horas antes da espirometria, caso estivessem em tratamento com BD de curta ação, e 48 horas antes, caso estivessem em tratamento com BD de ação prolongada. A mudança no percentual pós‐BD foi usada na análise estatística. Os critérios de resposta a BD, definidos como aumento de > 12% e 200 mL de VEF1 inicial, foram usados como o segundo modelo para avaliar a associação entre as variantes do gene da <span class="elsevierStyleItalic">IL‐8</span> e a resposta a BD.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Extração do DNA e genotipagem</span><p id="par0050" class="elsevierStylePara elsevierViewall">O DNA genômico foi extraído de amostras de sangue periférico com o método padrão fenol‐clorofórmio e quantificado por espectrofotômetro GE NanoVue™ (GE Healthcare Biosciences, Pittsburgh, EUA). Neste estudo, a concentração final da amostra foi estabelecida em 50 ng/μL.</p><p id="par0055" class="elsevierStylePara elsevierViewall">As mutações do <span class="elsevierStyleItalic">RTFC</span> foram analisadas por reação em cadeia da polimerase (PCR) (F508del) após digestão enzimática (G542X, R1162X, R553X, G551D e N1303 K). Outras mutações no gene do <span class="elsevierStyleItalic">RTFC</span> podem ser identificadas por sequenciamento ou com o uso do método SALSA MPLA (Amplificação de Múltiplas Sondas Dependentes de Ligação) Kit P091‐C1 CFTR‐MRC‐Holland S4X, 2183A > G, 1717‐G > A, I618 T com MegaBace1000<span class="elsevierStyleSup">®</span> (GE Healthcare Biosciences, Pittsburgh, EUA) e ABI3500 (Biossistemas Aplicados – Thermo Fisher Scientific, São Paulo, Brasil).<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">17</span></a></p><p id="par0060" class="elsevierStylePara elsevierViewall">As variantes do gene da <span class="elsevierStyleItalic">IL‐8</span> foram analisadas por PCR após digestão com enzimas de restrição. Para a variante rs4073, foram usados os iniciadores 5’‐CCA TCA TGA TAG CAT CTG TA‐3′ e 5′‐CCA CAA TTT GGT GAA TTA TTA A‐3′ e a enzima de restrição <span class="elsevierStyleItalic">AseI</span>; para a variante rs2227306, foram usados os iniciadores 5′‐CTC TAA CTC TTT ATA TAG GAA TT‐3′ e 5′‐GAT TGA TTT TAT CAA CAG GCA‐3′, bem como a enzima de restrição <span class="elsevierStyleItalic">EcoRI</span>; e para a variante rs2227307, foram usados os iniciadores 5′‐TAA AGG TTT GAT CAA TAT AGA‐3′ e 5′‐CTT CCT TCT AAT TCCA ATA TG‐3′, bem como a enzima de restrição <span class="elsevierStyleItalic">ScrFI</span>.<a class="elsevierStyleCrossRefs" href="#bib0240"><span class="elsevierStyleSup">18,19</span></a> Os produtos da restrição enzimática foram submetidos a eletroforese em gel de poliacrilamida a 12%, ou gel de agarose a 4%,<a class="elsevierStyleCrossRefs" href="#bib0240"><span class="elsevierStyleSup">18,19</span></a> e corados com gel Red<span class="elsevierStyleSup">®</span>.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Análise estatística</span><p id="par0065" class="elsevierStylePara elsevierViewall">Foi feita com a versão 22.0 do SPSS (SPSS Inc., Chicago, EUA). Foi usada a versão 3.1.9.2<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">20</span></a> do <span class="elsevierStyleItalic">software</span> GPower para calcular o poder da amostra, considerou‐se o genótipo das variantes analisadas e adotou‐se o poder para valor acima de 80%. As condições a seguir foram aplicadas para calcular o poder da amostra: (teste de análise da variância no lugar do teste de Kruskal‐Wallis, considerou‐se que a análise de variância é um teste mais forte) tamanho do efeito<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,25, α<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,05, poder<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,80, grau de liberdade do numerador<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>2, número de grupos<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>3, n° ideal<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>158; (teste de Mann‐Whitney–bicaudal) tamanho do efeito<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,5, α<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,05, poder<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,80, proporção de atribuição N2/N1<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1, n° ideal–134; (teste χ<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">2</span></a>) tamanho do efeito<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,3, α<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,05, poder<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,80, grau de liberdade<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>2, n° ideal<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>108.</p><p id="par0070" class="elsevierStylePara elsevierViewall">Os testes de Mann‐Whitney e Kruskal‐Wallis foram usados para comparação entre diferentes genótipos e os grupos de variantes do gene da <span class="elsevierStyleItalic">IL‐8</span> e a resposta a BD. Em caso de diferenças significativas entre os grupos do teste de Kruskal‐Wallis, foram feitas identificação e avaliação adicionais das diferenças entre os genótipos com o <span class="elsevierStyleItalic">software</span> para Windows MedCalc<span class="elsevierStyleSup">®</span>, versão 16.1 (MedCalc<span class="elsevierStyleSup">®</span> Software, Ostend, Bélgica).</p><p id="par0075" class="elsevierStylePara elsevierViewall">O teste χ2 e o teste exato de Fisher foram usados para comparação entre os diferentes genótipos e grupos de variantes do gene da IL‐8 e a resposta a BD definidos como um aumento de > 12% e 200 mL de VEF1 inicial.</p><p id="par0080" class="elsevierStylePara elsevierViewall">Para a identificação de mutações no gene do <span class="elsevierStyleItalic">RTFC</span>, os pacientes foram analisados com base em dois contextos: (<span class="elsevierStyleItalic">RTFC</span>‐A) todos os pacientes com FC, independentemente das mutações do gene (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>186 pacientes); (<span class="elsevierStyleItalic">RTFC</span>‐B) pacientes com duas mutações pertencentes às classes I, II e/ou III (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>91 pacientes). Quanto às variantes, foram adotados quatro modelos de análise: (i) codominante (teste de Kruskal‐Wallis); (ii) recessivo (teste de Mann‐Whitney); (iii) dominante (teste de Mann‐Whitney); (iv) superdominante (teste de Mann‐Whitney), aplicados em associação às variáveis clínicas. Para todas as análises, o valor alfa foi estabelecido em 0,05.</p><p id="par0085" class="elsevierStylePara elsevierViewall">Para análise do equilíbrio de Hardy‐Weinberg (HWE) foi usado o <span class="elsevierStyleItalic">software</span> Online Encyclopedia for Genetic Epidemiology Studies (OEGE).</p><p id="par0090" class="elsevierStylePara elsevierViewall">O teste da taxa de falsa descoberta (FDR) foi aplicado para corrigir a comparação múltipla de testes. A FDR é uma abordagem ao problema de múltiplas comparações. Em vez de controlar a chance de qualquer falso, os controles da FDR controlam a proporção esperada de falsos positivos entre os resultados significativos. O limite da FDR é determinado a partir da distribuição do valor de p observado e, assim, é adaptativo ao valor de sinal nos dados.<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">21</span></a> O valor de p (p) e o valor de p corrigido (p<span class="elsevierStyleSup">c</span>) foram mostrados no manuscrito. A análise de desequilíbrio de ligação foi feita na versão 4.2 do <span class="elsevierStyleItalic">software</span> Haploview.</p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Resultados</span><p id="par0095" class="elsevierStylePara elsevierViewall">Os dados clínicos e laboratoriais dos pacientes com FC são descritos na <a class="elsevierStyleCrossRef" href="#tbl0010">tabela 2</a>. A descrição do genótipo e da frequência de alelos das variantes do gene da <span class="elsevierStyleItalic">IL‐8</span> encontra‐se na <a class="elsevierStyleCrossRef" href="#tbl0015">tabela 3</a>. A <a class="elsevierStyleCrossRef" href="#fig0005">figura 1</a> mostra os dados com valores de p e valor de p corrigido para associação das variantes do gene da <span class="elsevierStyleItalic">IL‐8</span>, consideraram‐se os quatros modelos de análise propostos e o genótipo do gene do <span class="elsevierStyleItalic">RTFC</span>.</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0100" class="elsevierStylePara elsevierViewall">A variante rs2227307 não foi associada à resposta a BD em nenhum dos modelos estudados; ao passo que a variante rs2227306 foi associada a FEF<span class="elsevierStyleInf">50%</span> para pacientes com genótipo CC (modelo dominante; p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,05; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,083) e genótipo CT (modelo superdominante; p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,033; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,083) no grupo <span class="elsevierStyleItalic">RTFC</span>‐B (<a class="elsevierStyleCrossRef" href="#fig0005">fig. 1</a>D e E).</p><p id="par0105" class="elsevierStylePara elsevierViewall">Deve‐se enfatizar de modo especial a variante rs4073, associada às variáveis de espirometria: FEV<span class="elsevierStyleInf">1</span>, proporção VEF<span class="elsevierStyleInf">1</span>/CVF, FEF<span class="elsevierStyleInf">50%</span>, FEF<span class="elsevierStyleInf">75%</span> e FEF<span class="elsevierStyleInf">25‐75%.</span> A menor resposta a BD foi observada para genótipo TT (modelo dominante) e pacientes do grupo <span class="elsevierStyleItalic">RTFC</span>‐B a VEF<span class="elsevierStyleInf">1</span> (<a class="elsevierStyleCrossRef" href="#fig0005">fig. 1</a>A), FEF<span class="elsevierStyleInf">50%</span> (<a class="elsevierStyleCrossRef" href="#fig0005">fig. 1</a> C), FEF<span class="elsevierStyleInf">75%</span> (<a class="elsevierStyleCrossRef" href="#fig0005">fig. 1</a>G) e FEF<span class="elsevierStyleInf">25‐75%</span> (<a class="elsevierStyleCrossRef" href="#fig0005">fig. 1</a> K). O mesmo foi observado para o grupo <span class="elsevierStyleItalic">RTFC</span>‐A para FEF<span class="elsevierStyleInf">75%</span> (<a class="elsevierStyleCrossRef" href="#fig0005">fig. 1</a>H) e FEF<span class="elsevierStyleInf">25‐75%</span> (<a class="elsevierStyleCrossRef" href="#fig0005">fig. 1</a>L). Na análise codominante, o genótipo TT apresentou menor resposta a BD para VEF<span class="elsevierStyleInf">75%</span> (<a class="elsevierStyleCrossRef" href="#fig0005">fig. 1</a>F) e FEF<span class="elsevierStyleInf">25‐75%</span> (<a class="elsevierStyleCrossRef" href="#fig0005">fig. 1</a> J), respectivamente para os grupos <span class="elsevierStyleItalic">RTFC</span>‐A e <span class="elsevierStyleItalic">RTFC</span>‐B. Para o indicador VEF<span class="elsevierStyleInf">1</span>/CVF, o genótipo AT nos pacientes do grupo <span class="elsevierStyleItalic">RTFC</span>‐B mostrou menor resposta a BD (<a class="elsevierStyleCrossRef" href="#fig0005">fig. 1</a>B). Por fim, nos pacientes dos grupos <span class="elsevierStyleItalic">RTFC</span>‐A e <span class="elsevierStyleItalic">RTFC</span>‐B, respectivamente, o genótipo AA (modelo recessivo) para rs4073 mostrou maior resposta a BD para FEF<span class="elsevierStyleInf">75%</span> (<a class="elsevierStyleCrossRef" href="#fig0005">fig. 1</a>I) e FEF<span class="elsevierStyleInf">25‐75%</span> (<a class="elsevierStyleCrossRef" href="#fig0005">fig. 1</a> M).</p><p id="par0110" class="elsevierStylePara elsevierViewall">A distribuição de haplótipos para as variantes do gene da <span class="elsevierStyleItalic">IL‐8</span> é apresentada na <a class="elsevierStyleCrossRef" href="#tbl0015">tabela 3</a>.</p><p id="par0115" class="elsevierStylePara elsevierViewall">Para comparação entre as variantes do gene da IL‐8 e a resposta a BD definida como aumento de > 12% e 200 mL de VEF1 inicial, não foi encontrada associação positiva (p > 0,05).</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Discussão</span><p id="par0120" class="elsevierStylePara elsevierViewall">Mostramos anteriormente a influência das diferentes variantes do gene da <span class="elsevierStyleItalic">IL‐8</span> sobre a gravidade clínica da FC.<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">22</span></a> Além disso, este estudo mostra a associação das diferentes variantes do gene da <span class="elsevierStyleItalic">IL‐8</span> e sua modulação à resposta a BD, avalia o impacto do medicamento sobre a função pulmonar. A variabilidade das respostas aos BD é determinada por vários fatores, como inflamação e obstrução pulmonar,<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">23</span></a> bactérias<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">24</span></a> e sintomas pulmonares,<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">25</span></a> bem como genes modificadores.<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">26</span></a> Contudo, até agora, nenhum estudo investigou o papel da <span class="elsevierStyleItalic">IL‐8</span> como mediador pró‐inflamatório de FC e sua relação aos BD e se as variantes do gene da <span class="elsevierStyleItalic">IL‐8</span> podem explicar a resposta individual aos BD na FC. Acredita‐se que os beta‐2 agonistas de curta e longa duração podem ser benéficos para pacientes com FC e com hiperresponsividade brônquica positiva.<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">6</span></a></p><p id="par0125" class="elsevierStylePara elsevierViewall">Em doenças pulmonares progressivas, foram avaliados diferentes marcadores e o uso dos BD parece fornecer melhor resposta ao FEF<span class="elsevierStyleInf">25‐75%</span>, em comparação com outros marcadores, o que indica envolvimento de vias aéreas de menor calibre na FC.<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">27</span></a> Nosso estudo, em concordância com a literatura de referência, encontrou uma associação da variante rs4073 para o marcador FEF<span class="elsevierStyleInf">25‐75%</span> nos modelos dominante (para os grupos <span class="elsevierStyleItalic">RTFC</span>‐A e <span class="elsevierStyleItalic">RTFC</span>‐B), codominante (grupo <span class="elsevierStyleItalic">RTFC</span>‐B) e recessivo (grupo <span class="elsevierStyleItalic">RTFC</span>‐B). Houve melhoria em diversos outros marcadores de espirometria para rs4073, como VEF<span class="elsevierStyleInf">1</span>, VEF<span class="elsevierStyleInf">1</span>/CVF e FEF<span class="elsevierStyleInf">50%</span> e FEF<span class="elsevierStyleInf">75%</span>, o que mostra impacto sobre os padrões de respiração dos pacientes.</p><p id="par0130" class="elsevierStylePara elsevierViewall">O estudo de Hillian et al. encontrou uma associação das variantes rs2227307 e rs4073 do gene da <span class="elsevierStyleItalic">IL‐8</span> e a gravidade da doença pulmonar.<a class="elsevierStyleCrossRef" href="#bib0290"><span class="elsevierStyleSup">28</span></a> Nesse estudo, os pacientes foram divididos em duas coortes: (1) pacientes homozigotos F508del; (2) pacientes com outros genótipos do gene do <span class="elsevierStyleItalic">RTFC</span>. Na coorte 1, as variantes rs4073, rs2227306 e rs2227543 não foram associadas a doença pulmonar e a variante rs22227307 mostrou associação, independentemente do sexo. Na coorte 2, as variantes rs4073 e rs2227306 foram associadas a gravidade da doença pulmonar em homens. Assim, o sexo do paciente, o genótipo do gene do <span class="elsevierStyleItalic">RTFC</span> e os genes modificadores podem modular a gravidade da doença pulmonar.<a class="elsevierStyleCrossRef" href="#bib0290"><span class="elsevierStyleSup">28</span></a> Nesse estudo, o genótipo rs2227307 não teve impacto sobre a variabilidade da resposta a BD. Isso sugere que, apesar de esse genótipo estar associado a doença pulmonar em pacientes homozigotos F508del, sua resposta a BD não é relevante.</p><p id="par0135" class="elsevierStylePara elsevierViewall">O alvo dos BD é a proteína ADRB2, expressa no músculo liso das vias aéreas. As variantes de ADRB2 estão associadas à resposta à medicação. Essa proteína foi amplamente estudada em asma e ainda muito raramente em FC. A eficácia da resposta a BD e aos corticosteroides inalatórios no manejo de inflamação das vias aéreas em asma está confirmada e depende das variantes Arg16Gly (rs1042713; c.46A<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>G) e Glu27Gln (rs1042714; c.79C<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>G) do gene <span class="elsevierStyleItalic">ADRB2</span>.[29] A variante Gln27Glu concede resistência à proteína ADRB2 na resposta a BD. Os alelos 46*G e 79*G protegem contra asma, reduzem o risco em 27%.<a class="elsevierStyleCrossRef" href="#bib0295"><span class="elsevierStyleSup">29</span></a> As variantes do alelo G induzem alterações na regulação do receptor, devido ao aumento da susceptibilidade à degradação de proteínas. Este estudo constatou que as variantes Arg16Gly e Gln27Glu do gene <span class="elsevierStyleItalic">ADRB2</span> influenciam a respostas aos BD na FC. Na espirometria e em outros marcadores de gravidade, a variante Arg16Gly mostrou associação positiva, ao contrário da variante Gln27Glu. O genótipo Arg/Arg da variante Arg16Gly foi associado a melhores valores de VEF<span class="elsevierStyleInf">1</span> e FEF<span class="elsevierStyleInf">25‐75%</span>. A resposta a BD nas análises de haplótipo foi positiva na ausência dos genótipos Gly16Gly e Glu27Glu para a proporção VEF<span class="elsevierStyleInf">1</span>/CVF.</p><p id="par0140" class="elsevierStylePara elsevierViewall">As variantes de ADRB2, capacidade de difusão dos pulmões para monóxido de carbono, condutância da membrana capilar alveolar, volume sanguíneo na capilar alveolar e SaO<span class="elsevierStyleInf">2</span>, foram avaliadas na resposta a BD em 18 pacientes e 20 controles saudáveis, antes e depois da administração de salbutamol (30, 60 e 90 minutos). Os indivíduos saudáveis não apresentaram alterações nos marcadores avaliados para a variante Glu27Glu. Contudo, na FC, essa variante influenciou a resposta a BD: a melhor resposta encontrada na presença de pelo menos um alelo 27Glu. Houve uma diferença de difusão pulmonar e SaO<span class="elsevierStyleInf">2</span> periférica de acordo com a variação do gene <span class="elsevierStyleItalic">ADRB2</span> na posição 27 e a dosagem do medicamento deve ser prescrita de acordo com essa variação.<a class="elsevierStyleCrossRef" href="#bib0300"><span class="elsevierStyleSup">30</span></a></p><p id="par0145" class="elsevierStylePara elsevierViewall">A maior parte dos estudos foca nas variantes do gene ADRB2 na resposta a BD. Contudo, este estudo demonstra que, mesmo indiretamente, as variantes do gene da <span class="elsevierStyleItalic">IL‐8</span> e possivelmente em outros genes, que modulam a resposta pulmonar inflamatória, podem potencializar ou diminuir o efeito dos BD e, ainda, influenciar a resposta ao medicamento.</p><p id="par0150" class="elsevierStylePara elsevierViewall">Com relação ao HWE, conforme discutido anteriormente por nosso grupo,<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">22</span></a> duas variantes (rs4073 e rs2227306) não estavam em equilíbrio. Devemos lembrar que o HWE pressupõe uma população ideal, sem a interferência de fatores evolucionários. Contudo, em genes envolvidos em controle de imunidade, inflamação e infecção, o desequilíbrio do HWE parecer estar associado de forma secundária aos mecanismos de seleção que favoreceram um alelo específico que pode trazer uma resposta mais efetiva. O desequilíbrio não invalida o estudo de associação, pois os grupos fazem parte da mesma população.</p><p id="par0155" class="elsevierStylePara elsevierViewall">Limitações do estudo: (i) banco de dados transversal (a resposta a BD foi avaliada em um único momento); (ii) há vários dados ausentes, se levarmos em consideração os problemas para obter as informações nos registros; (iii) caso a resposta a BD seja diferente com base no VEF<span class="elsevierStyleInf">1</span> de base, principalmente em indivíduos saudáveis; (iv) possíveis variáveis de confusão com relação aos resultados, como gravidade da doença, terapias atuais, adesão à medicação e esforço adequado no teste de função pulmonar.</p><p id="par0160" class="elsevierStylePara elsevierViewall">As variantes do gene da <span class="elsevierStyleItalic">IL‐8</span> (rs2227306 e especialmente rs4073) podem estar associadas à resposta a BD durante a espirometria. Esse medicamento pode ser uma opção para o tratamento da doença, na maior parte do tempo em pacientes com vias aéreas de menor calibre. Devem‐se conduzir estudos que envolvam dose e combinações de medicamentos para determinar o melhor tratamento de acordo com o genótipo do paciente com FC, o gene do <span class="elsevierStyleItalic">RTFC</span>, bem como os genes modificadores.</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Financiamento</span><p id="par0165" class="elsevierStylePara elsevierViewall">FALM: Fundação de Amparo à Pesquisa do Estado de São Paulo (Fapesp), em apoio às pesquisas n° 2011/12939‐4, n° 2011/18845‐1, n° 2015/12183‐8 e n° 2015/12858‐5; Fundo de Apoio à Pesquisa, ao Ensino e à Extensão da Universidade Estadual de Campinas, em apoio à pesquisa n° 0648/2015; JDR: Fapesp, em apoio às pesquisas n° 2011/18845‐1 e n° 2015/12183‐8. LLF: Fapesp, em apoio à pesquisa n° 2013/19052‐0.</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Conflitos de interesse</span><p id="par0170" class="elsevierStylePara elsevierViewall">Os autores declaram não haver conflitos de interesse.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres934979" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Objective" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec908956" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres934978" "titulo" => "Resumo" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0045" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0050" "titulo" => "Métodos" ] 2 => array:2 [ "identificador" => "abst0055" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0060" "titulo" => "Conclusões" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec908955" "titulo" => "Palavras‐chave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introdução" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Material e métodos" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Pacientes" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Variáveis clínicas" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Extração do DNA e genotipagem" ] 3 => array:2 [ "identificador" => "sec0030" "titulo" => "Análise estatística" ] ] ] 6 => array:2 [ "identificador" => "sec0035" "titulo" => "Resultados" ] 7 => array:2 [ "identificador" => "sec0040" "titulo" => "Discussão" ] 8 => array:2 [ "identificador" => "sec0045" "titulo" => "Financiamento" ] 9 => array:2 [ "identificador" => "sec0050" "titulo" => "Conflitos de interesse" ] 10 => array:2 [ "identificador" => "xack315684" "titulo" => "Agradecimentos" ] 11 => array:1 [ "titulo" => "Referências" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2016-08-02" "fechaAceptado" => "2017-01-09" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec908956" "palabras" => array:4 [ 0 => "<span class="elsevierStyleItalic">CFTR</span>" 1 => "Disease severity" 2 => "Interleukin 8" 3 => "Lung function" ] ] ] "pt" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palavras‐chave" "identificador" => "xpalclavsec908955" "palabras" => array:4 [ 0 => "<span class="elsevierStyleItalic">CFTR</span>" 1 => "Gravidade da doença" 2 => "Interleucina 8" 3 => "Função pulmonar" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Objective</span><p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Interleukin 8 protein promotes inflammatory responses, even in airways. The presence of interleukin 8 gene variants causes altered inflammatory responses and possibly varied responses to inhaled bronchodilators. Thus, this study analyzed the interleukin 8 variants (rs4073, rs2227306, and rs2227307) and their association with the response to inhaled bronchodilators in cystic fibrosis patients.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Methods</span><p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Analysis of interleukin 8 gene variants was performed by restriction fragment length polymorphism of polymerase chain reaction. The association between spirometry markers and the response to inhaled bronchodilators was evaluated by Mann‐Whitney and Kruskal‐Wallis tests. The analysis included all cystic fibrosis patients, and subsequently patients with two mutations in the cystic fibrosis transmembrane conductance regulator gene belonging to classes I to III.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0095" class="elsevierStyleSimplePara elsevierViewall">This study included 186 cystic fibrosis patients. There was no association of the rs2227307 variant with the response to inhaled bronchodilators. The rs2227306 variant was associated with FEF<span class="elsevierStyleInf">50%</span> in the dominant group and in the group with two identified mutations in the cystic fibrosis transmembrane conductance regulator gene. The rs4073 variant was associated with spirometry markers in four genetic models: co‐dominant (FEF<span class="elsevierStyleInf">25‐75%</span> and FEF<span class="elsevierStyleInf">75%</span>), dominant (FEV<span class="elsevierStyleInf">1</span>, FEF<span class="elsevierStyleInf">50%</span>, FEF<span class="elsevierStyleInf">75%</span>, and FEF<span class="elsevierStyleInf">25‐75%</span>), recessive (FEF<span class="elsevierStyleInf">75%</span> and FEF<span class="elsevierStyleInf">25‐75%</span>), and over‐dominant (FEV<span class="elsevierStyleInf">1</span>/FVC).</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0100" class="elsevierStyleSimplePara elsevierViewall">This study highlighted the importance of the rs4073 variant of the interleukin 8 gene, regarding response to inhaled bronchodilators, and of the assessment of mutations in the cystic fibrosis transmembrane conductance regulator gene.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Objective" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] "pt" => array:3 [ "titulo" => "Resumo" "resumen" => "<span id="abst0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Objetivo</span><p id="spar0105" class="elsevierStyleSimplePara elsevierViewall">A proteína interleucina 8 promove respostas inflamatórias, o que inclui sua atuação nas vias aéreas. A presença de variantes no gene da interleucina 8 causa respostas inflamatórias alteradas e possivelmente respostas variadas ao uso de broncodilatadores inalatórios. Assim, este estudo analisou as variantes da interleucina 8 (rs4073, rs2227306, rs2227307) e sua associação à resposta a broncodilatadores inalatórios em pacientes com fibrose cística.</p></span> <span id="abst0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Métodos</span><p id="spar0110" class="elsevierStyleSimplePara elsevierViewall">Foi feita análise das variantes genéticas da interleucina 8 por <span class="elsevierStyleItalic">restriction fragment length polymorphism</span> da reação em cadeia da polimerase. A associação entre os marcadores da espirometria e a resposta a broncodilatadores inalatórios foi feita pelos testes de Mann‐Whitney e Kruskal‐Wallis. A análise incluiu todos os pacientes com fibrose cística e posteriormente pacientes com duas mutações no gene <span class="elsevierStyleItalic">cystic fibrosis transmembrane conductance regulator</span> pertencentes às Classes I a II.</p></span> <span id="abst0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Resultados</span><p id="spar0115" class="elsevierStyleSimplePara elsevierViewall">Este estudo incluiu 186 pacientes com fibrose cística. Não houve associação da variante rs2227307 à resposta a broncodilatadores inalatórios. A variante rs2227306 foi associada a FEF<span class="elsevierStyleInf">50%</span> no grupo dominante e no grupo com duas mutações identificadas no gene <span class="elsevierStyleItalic">cystic fibrosis transmembrane conductance regulator</span>. A variante rs4073 foi associada a marcadores da espirometria em quatro modelos genéticos: codominante (FEF<span class="elsevierStyleInf">25‐75%</span> e FEF<span class="elsevierStyleInf">75%</span>), dominante (VEF<span class="elsevierStyleInf">1</span>, FEF<span class="elsevierStyleInf">50%</span>, FEF<span class="elsevierStyleInf">75%</span> e FEF<span class="elsevierStyleInf">25‐75%</span>), recessivo (FEF<span class="elsevierStyleInf">75%</span> e FEF<span class="elsevierStyleInf">25‐75%</span>) e overdominante (VEF<span class="elsevierStyleInf">1</span>/CVF).</p></span> <span id="abst0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Conclusões</span><p id="spar0120" class="elsevierStyleSimplePara elsevierViewall">Este estudo destaca, principalmente, a importância da variante rs4073 do gene da interleucina 8, na resposta a broncodilatadores inalatórios, concomitantemente ao genótipo das mutações no gene <span class="elsevierStyleItalic">cystic fibrosis transmembrane conductance regulator</span>.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0045" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0050" "titulo" => "Métodos" ] 2 => array:2 [ "identificador" => "abst0055" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0060" "titulo" => "Conclusões" ] ] ] ] "NotaPie" => array:2 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0030">Como citar este artigo: Furlan LL, Ribeiro JD, Bertuzzo CS, Salomão Junior JB, Souza DR, Marson FA. Variants in the interleukin 8 gene and the response to inhaled bronchodilators in cystic fibrosis. J Pediatr (Rio J). 2017;93:639–48.</p>" ] 1 => array:2 [ "etiqueta" => "☆☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0035">Estudo feito na Universidade Estadual de Campinas (Unicamp), Campinas, SP, Brasil.</p>" ] ] "multimedia" => array:4 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 4239 "Ancho" => 3276 "Tamanyo" => 668369 ] ] "descripcion" => array:1 [ "pt" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Associação das variantes rs4073 e rs2227306 da <span class="elsevierStyleItalic">IL‐8</span> (interleucina‐8) à resposta a broncodilatadores inalatórios em pacientes com fibrose cística. A. Associação entre o volume expiratório forçado no 1° segundo (VEF<span class="elsevierStyleInf">1</span>) da capacidade vital forçada (CVF) e rs4073, modelo dominante e duas mutações identificadas no gene do <span class="elsevierStyleItalic">RTFC</span> (regulador da condutância transmembrana da fibrose cística) pertencente às classes I, II e/ou III (grupo <span class="elsevierStyleItalic">RTFC</span>‐B) (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,028; p<span class="elsevierStyleSup">c</span>–0,112). (AA +<span class="elsevierStyleHsp" style=""></span>AT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>39; média de 4,77<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>8,95; mediana de 4 (variação de −9 a 48). (TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>21; média de 0,86<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>5,42; mediana de −1 (variação de −6 a 15). B. Associação da proporção VEF1/CVF à variante rs4073, modelo superdominante e grupo <span class="elsevierStyleItalic">RTFC</span>‐B (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,029; pc<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,116). (TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>30; média de 0,86<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>7,36; mediana de 0 (variação de −12 a 23). (AT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>29; média de 4,76<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>7,58; mediana de 4 (variação de −9 a 32). C. Associação do fluxo expiratório forçado de 50% (FEF<span class="elsevierStyleInf">50%</span>) da CVF à variante rs4073, modelo dominante e grupo <span class="elsevierStyleItalic">RTFC</span>‐B (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,046; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,184). (AA<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>AT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>37; média de 17,38<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>24,18; mediana de 16 (variação de −20 a 89). (TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>21; média de 4,95<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>20,80; mediana de −2 (variação de −19 a 55). D. Associação do FEF<span class="elsevierStyleInf">50%</span> à variante rs2227306, modelo dominante e grupo <span class="elsevierStyleItalic">RTFC‐B</span> (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,050; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,083). (CC) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>15; média de 1,47<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>17,22; mediana de 0 (variação de −20 a 29). (CT<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>44; média de 15,84<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>25,04; mediana de 10,50 (variação de −28 a 89). E. Associação do FEF<span class="elsevierStyleInf">50%</span> à variante rs2227306, modelo superdominante e grupo <span class="elsevierStyleItalic">RTFC</span>‐B (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,033; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,083). (CC<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>33; média de 6,06<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>20,27; mediana de 4 (variação de −20 a 55). (CT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>23; média de 19,96<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>26,43; mediana de 19 (variação de −28 a 89). F. Associação do fluxo expiratório forçado de 75% (FEF<span class="elsevierStyleInf">75%</span>) da CVF à variante rs4073, modelo codominante independentemente das mutações identificadas no gene do <span class="elsevierStyleItalic">RTFC</span> (grupo RTFC‐A) (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,044; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,058). 1 ≠ 3. (AA) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>28; média de 29,93<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>39,98; mediana de 30 (variação de −47 a 142). (AT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>42; média de 24,81<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>53,57; mediana de 14 (variação de −58 a 235). (TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>28; média de 9,14<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>36,95; mediana de 2,5 (variação de −35 a 119). G. Associação do FEF<span class="elsevierStyleInf">75%</span> à variante rs4073, modelo dominante e grupo <span class="elsevierStyleItalic">RTFC</span>‐B (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,024; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,096). (AA<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>AT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>38; média de 33<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>55,23; mediana de (variação de −27 a 235). (TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>21; média de 5,43<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>35,93; mediana de 2 (variação de −35 a 119). H. Associação do FEF<span class="elsevierStyleInf">75%</span> à variante rs4073, modelo dominante e grupo <span class="elsevierStyleItalic">RTFC‐A</span> (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,034; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,058). (AA<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>AT) (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>70; média de 26,86<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>48,34; mediana de 18 (variação de −58 a 235). (TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>28; média de 9,14<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>36,95; mediana de 2,5 (variação de −35 a 119). I. Associação do FEF<span class="elsevierStyleInf">75%</span> à variante rs4073, modelo recessivo e grupo <span class="elsevierStyleItalic">RTFC‐A</span> (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,040; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,058). (AA) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>28; média de 29,93<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>39,98; mediana de 30 (variação de −47 a 142). (AT<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>70; média de 18,54<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>47,95; mediana de 10 (variação de −58 a 235). J. Associação do FEF entre 25 e 75% (FEF<span class="elsevierStyleInf">25‐75%</span>) da CVF à variante rs4073, modelo codominante e grupo <span class="elsevierStyleItalic">RTFC‐B</span> (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,012; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,024). TT ≠ AA e AT. (AA) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>9; média de 25,78<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>23,14; mediana de 30 (variação de −21 a 57). (AT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>29; média de 18,38<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>29,04; mediana de 14 (variação de −33 a 117). (TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>21; média de 2,14<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>23,74; mediana de 0 (variação de −51 a 65). K. Associação do FEF<span class="elsevierStyleInf">25‐75%</span> à variante rs4073, modelo dominante e grupo <span class="elsevierStyleItalic">RTFC‐B</span> (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,007; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,024). (AA<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>ATT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>38; média de 20,13<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>27,64; mediana de 18,50 (variação de −33 a 117). (TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>23; média de 2,14<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>23,74; mediana de 0 (variação de −51 a 65). L. Associação do FEF<span class="elsevierStyleInf">25‐75%</span> à variante rs4073, modelo dominante e grupo <span class="elsevierStyleItalic">RTFC‐A</span> (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,029; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,100). (AA<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>AT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>82; média de 15,48<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>27,20; mediana de 15 (variação de −40 a 117). (TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>33; média de 5,94<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>27,33; mediana de 0 (variação de −51 a 76). M. Associação do FEF<span class="elsevierStyleInf">25‐75%</span> à variante rs4073, modelo recessivo e grupo <span class="elsevierStyleItalic">RTFC‐B</span> (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,047; p<span class="elsevierStyleSup">c</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,063). (AA) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>9; média de 25,78<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>23,14; mediana de 30 (variação de −21 a 57). (AT<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>TT) n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>50; média de 11,56<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>27,89; mediana de 8 (variação de −51 a 117). O ponto corresponde aos valores medianos e a barra corresponde a intervalo de confiança de 95%.</p>" ] ] 1 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Tabela 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Tabela " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">N, tamanho da amostra; <span class="elsevierStyleItalic">RTFC</span>, regulador da condutância transmembrana da fibrose cística.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Genótipo \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">N \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">% \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Grupo de pacientes \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>−<span class="elsevierStyleHsp" style=""></span>/‐ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">55 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">29,6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " rowspan="6" align="left" valign="top">Pacientes sem mutação no gene do <span class="elsevierStyleItalic">RTFC</span> ou com uma ou duas mutações pertences às classes IV, V ou VI</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">V562I/‐ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">I507V/‐ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">D110H/V232H \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">G576A/R668 C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">p.Glu528G<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>A/TG11‐5 T \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F508del/‐ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">23 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">12,4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " rowspan="10" align="left" valign="top">Pacientes com uma mutação do RTFC pertencentes às classes I, II ou III e uma mutação não identificada ou pertencentes às classes IV, V ou VI</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">G542X/‐ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2,2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F508del/3272‐26A<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>G \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F508del/P205S \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">G542X/P205S \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">G542X/R334 W \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">3120<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>1G<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>A/L206 W \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">622‐2A<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>G/711<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>1G<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>T \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">R1162X/‐ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">G542X/I618 T \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F508del/F508del \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">49 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">26,3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " rowspan="22" align="left" valign="top">Pacientes com duas mutações do <span class="elsevierStyleItalic">RTFC</span> pertencentes às classes I, II e/ou III<br><span class="elsevierStyleHsp" style=""></span>−<span class="elsevierStyleHsp" style=""></span>Mutações G2<br>(grupo <span class="elsevierStyleItalic">CFTR‐B</span>)</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F508del/G542X \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F508del/N1303 K \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2,7 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F508del/R1162X \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1,6 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F508del/R553X \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1,6 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F508del/1584‐18672pbA<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>G \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F508del/c.1717‐1G<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>A \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">3120<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>1G<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>A/R1066 C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F508del/2183AA<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>G \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F508del/2184insA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Duplicação do éxon F508del/6B a 16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F508del/G85E \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F508del/S549R (T<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>G) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F508del/S4X \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">G542X/2183AA<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>G \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">G542X/R1162X \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">A561E/A561E \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F508del/R1066 C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">R1070Q; S466X/G542X \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">F508del/1812‐1G<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>A \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">2183AA<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>G/2183AA<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>G \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">3120<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>1G<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>A/3120<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>1G<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>A \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1580263.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Todos os pacientes avaliados neste estudo foram incluídos (grupo <span class="elsevierStyleItalic">RTFC</span>‐A).</p>" ] ] ] "descripcion" => array:1 [ "pt" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Distribuição dos pacientes com fibrose cística para genótipo do <span class="elsevierStyleItalic">RTFC</span> e classes de mutações identificadas.<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a></p>" ] ] 2 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Tabela 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Tabela " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">CVF, capacidade vital forçada; FEF<span class="elsevierStyleInf">25%</span>, fluxo expiratório forçado a 25% da CVF; FEF<span class="elsevierStyleInf">25‐75%</span>, médio do fluxo expiratório forçado entre 25% e 75% da CVF; FEF<span class="elsevierStyleInf">50%</span>, fluxo expiratório forçado a 50% da CVF; FEF<span class="elsevierStyleInf">75%</span>, fluxo expiratório forçado a 75% da CVF; FEF<span class="elsevierStyleInf">max</span>, fluxo expiratório forçado máximo; SaO<span class="elsevierStyleInf">2</span>, saturação de oxigênio no sangue arterial; VEF<span class="elsevierStyleInf">1</span>, volume expiratório forçado no 1° segundo da CVF; VRE, volume de reserva expiratória.</p><p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Os dados da espirometria são mostrados em percentual de valor preditivo. Todos os pacientes avaliados são descritos.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Variáveis \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Distribuição<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Sexo (masculino)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">92/186 (49,5%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Etnia (branca)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">169/180 (93,9%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Idade (meses)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">169; 201,41<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>171,98; 143 (7 a 932) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Início dos sintomas (meses)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">159; 38,23<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>114,03; 3 (0 a 720) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Diagnóstico (meses)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">171; 87,90<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>158,39; 20 (0 a 833) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Início dos sintomas digestivos (meses)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">140; 41,2<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>112,61; 3 (0 a 720) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Início dos sintomas pulmonares (meses)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">156; 46,33<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>123,64; 6 (0 a 720) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Índice de massa corporal</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">178; 17,28<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>4,08; 16,28 (6,5 a 35,67) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Polipose nasal (presença)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">28/162 (17,3%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Diabetes mellitus <span class="elsevierStyleItalic">(presença)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">32/164 (19,5%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Osteoporose (presença)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">25/162 (15,4%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Insuficiência pancreática (presença)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">130/162 (80,2%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Íleo meconial (presença)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">23/162 (14,2%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">1ª</span> Pseudomonas aeruginosa \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">121; 103,03<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>171,74; 31 (0 a 872)<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">P. aeruginosa mucoide <span class="elsevierStyleItalic">(presença)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">74/173 (42,8%)<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">P. aeruginosa <span class="elsevierStyleItalic">não mucoide (presença)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">99/173 (57,2%)<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Achromobacter xylosoxidans <span class="elsevierStyleItalic">(presença)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">17/174 (9,8%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Burkolderia cepacia <span class="elsevierStyleItalic">(presença)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">25/174 (14,4%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Staphylococcus aureus <span class="elsevierStyleItalic">(presença)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">131/174 (75,3%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">SaO</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">2</span></span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">159; 94,87<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>4,28; 96 (66 a 99) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Escore de Bhalla</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">113; 8,9<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>5,77; 8 (0 a 25) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Escore de Kanga</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">118; 18,78<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>5,82; 17,5 (10 a 40) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Escore de Shwachman‐Kulczycki</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">143; 65,97<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>16,78; 65 (20 a 95) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">CVF</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">142; 72,13<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>23,86; 77 (19 a 126) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">FEV</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">1</span></span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">141; 60,99<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>25,75; 63 (17 a 116) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">VEF</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">1</span></span><span class="elsevierStyleItalic">/CVF</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">144; 79,08<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>14,99; 81 (39 a 113) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">FEF</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">25%</span></span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">119; 61,28<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>31,71; 60 (7 a 138) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">FEF</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">50%</span></span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">119; 46,2<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>31,25; 40 (3 a 126) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">FEF</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">75%</span></span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">116; 36,32<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>28,77; 27,5 (4 a 142) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">FEF</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">25‐75%</span></span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">140; 47,16<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>32,51; 39 (5 a 150) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">FEF</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">Max</span></span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">114; 75,54<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>25,59; 73,5 (25 a 137) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">VRE</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">112; 80,96<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>52,39; 69 (3 a 248) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Resposta a broncodilatador inalatório</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>CVF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">117; 1,74<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>8,19; 1 (−17 a 32) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>FEV<span class="elsevierStyleInf">1</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">117; 3,51<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>8,0; 3 (−12 a 48) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>VEF<span class="elsevierStyleInf">1</span>/CVF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">111; 2,14<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>7,43; 2 (−19 a 32) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>FEF<span class="elsevierStyleInf">25%</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">99; 9,99<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>24,41; 5 (−45 a 110) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>FEF<span class="elsevierStyleInf">50%</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">99; 13,08<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>26,06; 9 (−41 a 114) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>FEF<span class="elsevierStyleInf">75%</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">99; 20,93<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>46,47; 16 (−64 a 235) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>FEF<span class="elsevierStyleInf">25‐75%</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">99; 12,28<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>27,77; 9,5 (−51 a 117) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>FEF<span class="elsevierStyleInf">Max</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">116; 2,63<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>14,48; 3 (−42 a 69) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>VRE \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">100; 23,04<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>101,08; 0 (−90 a 670) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1580261.png" ] ] ] "notaPie" => array:3 [ 0 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Os dados com distribuição categórica são apresentados da seguinte forma: n° de variáveis/n° total (percentual); os dados com distribuição numérica são apresentados da seguinte forma: tamanho da amostra; média<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>desvio padrão; mediana (mínimo a máximo).</p>" ] 1 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Os valores ausentes para primeira <span class="elsevierStyleItalic">P. aeruginosa</span> correspondem a pacientes com fibrose cística que nunca apresentaram cultura positiva para <span class="elsevierStyleItalic">P. aeruginosa</span>.</p>" ] 2 => array:3 [ "identificador" => "tblfn0020" "etiqueta" => "c" "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Um paciente com fibrose cística apresentou cultura positiva para <span class="elsevierStyleItalic">P. aeruginosa</span>, com valores negativos para IgG específico do antígeno <span class="elsevierStyleItalic">P. aeruginosa</span> e o paciente foi excluído para estimativa de frequência.</p>" ] ] ] "descripcion" => array:1 [ "pt" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Análise descritiva dos marcadores clínicos e laboratoriais de pacientes com fibrose cística</p>" ] ] 3 => array:8 [ "identificador" => "tbl0015" "etiqueta" => "Tabela 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at3" "detalle" => "Tabela " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">fa, frequência absoluta; <span class="elsevierStyleItalic">IL‐8</span>, interleucina 8; %, percentual; χ<span class="elsevierStyleSup">2</span>, qui‐quadrado.</p>" "tablatextoimagen" => array:2 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Variantes \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Genótipo \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Número (%) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Alelo \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Número (fa) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">χ<span class="elsevierStyleSup">2</span> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Valor de p<a class="elsevierStyleCrossRef" href="#tblfn0025"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " rowspan="4" align="left" valign="top">rs4073</td><td class="td" title="table-entry " align="left" valign="top">AA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">54 (29,2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">A \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">187 (0,51) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " rowspan="3" align="left" valign="top">3,94</td><td class="td" title="table-entry " rowspan="3" align="left" valign="top">< 0,05</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">AT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">79 (42,7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">T \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">183 (0,49) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">TT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">52 (28,1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">370 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">185 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="7" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="4" align="left" valign="top">rs2227306</td><td class="td" title="table-entry " align="left" valign="top">CC \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">70 (38) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">211 (0,57) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " rowspan="3" align="left" valign="top">8,21</td><td class="td" title="table-entry " rowspan="3" align="left" valign="top">< 0,05</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">CT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">71 (38,6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">T \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">157 (0,43) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">TT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">43 (23,4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">368 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">184 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="7" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="4" align="left" valign="top">rs2227307</td><td class="td" title="table-entry " align="left" valign="top">GG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">31 (17,4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">G \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">139 (0,39) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " rowspan="3" align="left" valign="top">1,48</td><td class="td" title="table-entry " rowspan="3" align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>0,05</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">TG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">77 (43,3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">T \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">217 (0,61) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">TT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">70 (39,3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">356 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">178 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1580260.png" ] ] 1 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">rs4073/rs2227306/rs2227307 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Frequência \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Percentual (%) \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">AA CC GG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1,7 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">AA CC GT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2,8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">AA CC TT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">13,6 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">AA CT GG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1,7 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">AA CT GT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2,3 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">AA CT TT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4,0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">AA TT GG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1,1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">AA TT GT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1,1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">AA TT TT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1,7 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">AT CC GT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7,3 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">AT CC TT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4,0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">AT CT GT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">30 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">16,9 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">AT CT TT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5,6 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">AT TT GG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2,8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">AT TT GT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3,4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">AT TT TT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1,7 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">TT CC GG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1,1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">TT CC GT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2,8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">TT CC TT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4,5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">TT CT GG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2,3 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">TT CT GT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3,4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">TT CT TT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1,7 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">TT TT GG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6,8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">TT TT GT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2,8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">TT TT TT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2,8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">177 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">100 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1580262.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0025" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0025">χ<span class="elsevierStyleSup">2</span> e valores de p fazem referência ao cálculo de equilíbrio de Hardy‐Weinberg. Os dados significativos são mostrados em negrito. Houve uma fraca correlação entre as variantes do gene da <span class="elsevierStyleItalic">IL‐8</span> nos pacientes com fibrose cística inscritos no estudo. Não há desequilíbrio de ligação.</p>" ] ] ] "descripcion" => array:1 [ "pt" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Distribuição de genótipos, alelos e haplótipo das variantes do gene da <span class="elsevierStyleItalic">IL‐8</span> (rs4073, rs2227306 e rs2227307) em pacientes com fibrose cística</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "Referências" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:30 [ 0 => array:3 [ "identificador" => "bib0155" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Polymorphisms in ADRB2 gene can modulate the response to bronchodilators and the severity of cystic fibrosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "F.A.L. Marson" 1 => "C.S. Bertuzzo" 2 => "A.F. Ribeiro" 3 => "J.D. Ribeiro" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-2466-12-50" "Revista" => array:6 [ "tituloSerie" => "BMC Pulm Med" "fecha" => "2012" "volumen" => "12" "paginaInicial" => "50" "paginaFinal" => "59" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22950544" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0160" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Vankeerberghen" 1 => "H. Cuppens" 2 => "J.J. Cassiman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Cyst Fibros" "fecha" => "2002" "volumen" => "1" "paginaInicial" => "13" "paginaFinal" => "29" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15463806" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0165" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Essential involvement of interleukin‐8 (IL‐8) in acute inflammation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A. Harada" 1 => "N. Sekido" 2 => "T. Akahoshi" 3 => "T. Wada" 4 => "N. Mukaida" 5 => "K. Matsushima" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Leukoc Biol" "fecha" => "1994" "volumen" => "56" "paginaInicial" => "559" "paginaFinal" => "564" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7964163" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0170" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inhaled bronchodilators for cystic fibrosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C. Halfhide" 1 => "H.J. Evans" 2 => "J. Couriel" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Cochrane Database Syst Rev" "fecha" => "2005" "volumen" => "19" "paginaInicial" => "CD003428" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0175" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lung function testing in preschool‐aged children with cystic fibrosis in the clinical setting" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "C.L. Gangell" 1 => "G.L. Hall" 2 => "S.M. Stick" 3 => "P.D. Sly" 4 => "C.F. Arest" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/ppul.21192" "Revista" => array:6 [ "tituloSerie" => "Pediatr Pulmonol" "fecha" => "2010" "volumen" => "45" "paginaInicial" => "419" "paginaFinal" => "433" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20425849" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0180" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "WITHDRAWN: inhaled bronchodilators for cystic fibrosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C. Halfhide" 1 => "H.J. Evans" 2 => "J. Couriel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/14651858.CD003428.pub3" "Revista" => array:5 [ "tituloSerie" => "Cochrane Database Syst Rev" "fecha" => "2016" "volumen" => "2" "paginaInicial" => "CD003428" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26866910" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0185" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biochemical basis of asthma therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "P.J. Barnes" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1074/jbc.R110.206466" "Revista" => array:6 [ "tituloSerie" => "J Biol Chem" "fecha" => "2011" "volumen" => "286" "paginaInicial" => "32899" "paginaFinal" => "32905" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21799015" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0190" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Association of CFTR gene mutation with bronchial asthma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "N. Maurya" 1 => "S. Awasthi" 2 => "P. Dixit" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Indian J Med Res" "fecha" => "2012" "volumen" => "135" "paginaInicial" => "469" "paginaFinal" => "478" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22664493" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0195" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Regamey" 1 => "L. Tsartsali" 2 => "T.N. Hilliard" 3 => "O. Fuchs" 4 => "H.L. Tan" 5 => "J. Zhu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/thoraxjnl-2011-200585" "Revista" => array:6 [ "tituloSerie" => "Thorax" "fecha" => "2012" "volumen" => "67" "paginaInicial" => "164" "paginaFinal" => "170" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22008188" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0200" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "CFTR mutations and GSTM1 and GSTT1 deletions in Brazilian cystic fibrosis patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "C.S. Lima" 1 => "M.M. Ortega" 2 => "F.A.L. Marson" 3 => "R. Zulli" 4 => "A.F. Ribeiro" 5 => "C.S. Bertuzzo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Bras Pneumol" "fecha" => "2012" "volumen" => "38" "paginaInicial" => "50" "paginaFinal" => "56" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22407040" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0205" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The ACE gene D/I polymorphism as a modulator of severity of cystic fibrosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "F.A. Marson" 1 => "C.S. Bertuzzo" 2 => "T.D. Hortencio" 3 => "J.D. Ribeiro" 4 => "L.C. Bonadia" 5 => "A.F. Ribeiro" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-2466-12-41" "Revista" => array:5 [ "tituloSerie" => "BMC Pulm Med" "fecha" => "2012" "volumen" => "12" "paginaInicial" => "41" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22874010" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0210" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Polymorphisms in the glutathione pathway modulate cystic fibrosis severity: a cross‐sectional study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "F.A. Marson" 1 => "C.S. Bertuzzo" 2 => "A.F. Ribeiro" 3 => "J.D. Ribeiro" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-2350-15-27" "Revista" => array:5 [ "tituloSerie" => "BMC Med Genet" "fecha" => "2014" "volumen" => "15" "paginaInicial" => "27" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24593045" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0215" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Personalized drug therapy in cystic fibrosis: from fiction to reality" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "F.A. Marson" 1 => "C.S. Bertuzzo" 2 => "J.D. Ribeiro" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Curr Drug Targets" "fecha" => "2015" "volumen" => "16" "paginaInicial" => "1007" "paginaFinal" => "1017" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25438972" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0220" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pulmonary function testing in children: techniques and standards" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "G. Polgar" 1 => "V. Promadhat" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "1971" "editorial" => "WB Saunders Company" "editorialLocalizacion" => "Philadelphia (PA)" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0225" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "New reference values for forced spirometry in white adults in Brazil" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C.A. Pereira" 1 => "T. Sato" 2 => "S.C. Rodrigues" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Bras Pneumol" "fecha" => "2007" "volumen" => "33" "paginaInicial" => "397" "paginaFinal" => "406" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17982531" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0230" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Validation of new Brazilian predicted values for forced spirometry in Caucasians and comparison with predicted values obtained using other reference equations" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A.A. Duarte" 1 => "C.A. Pereira" 2 => "S.C. Rodrigues" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Bras Pneumol" "fecha" => "2007" "volumen" => "33" "paginaInicial" => "527" "paginaFinal" => "535" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18026650" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0235" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L.C. Bonadia" 1 => "F.A. Marson" 2 => "J.D. Ribeiro" 3 => "I.A. Paschoal" 4 => "M.C. Pereira" 5 => "A.F. Ribeiro" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.gene.2014.02.040" "Revista" => array:6 [ "tituloSerie" => "Gene" "fecha" => "2014" "volumen" => "540" "paginaInicial" => "183" "paginaFinal" => "190" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24583165" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0240" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Association study suggests opposite effects of polymorphisms within IL‐8 on bronchial asthma and respiratory syncytial virus bronchiolitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A. Heinzmann" 1 => "I. Ahlert" 2 => "T. Kurz" 3 => "R. Berner" 4 => "K.A. Deichmann" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2004.06.038" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2004" "volumen" => "114" "paginaInicial" => "671" "paginaFinal" => "676" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15356575" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0245" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Haplotypes in the interleukin 8 gene and their association with chronic periodontitis susceptibility" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.M. Scarel-Caminaga" 1 => "Y.J. Kim" 2 => "A.C. Viana" 3 => "K.M. Curtis" 4 => "S.C. Corbi" 5 => "P.M. Sogumo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10528-010-9407-3" "Revista" => array:6 [ "tituloSerie" => "Biochem Genet" "fecha" => "2011" "volumen" => "49" "paginaInicial" => "292" "paginaFinal" => "302" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21188496" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0250" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "GPower 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "F. Faul" 1 => "E. Erdfelde" 2 => "A.G. Lang" 3 => "A. Buchner" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Behav Res Methods" "fecha" => "2007" "volumen" => "39" "paginaInicial" => "175" "paginaFinal" => "191" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17695343" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0255" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Discovering the false discovery rate" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Y. Benjamini" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J R Stat Soc Ser B (Stat Method)" "fecha" => "2010" "volumen" => "72" "paginaInicial" => "405" "paginaFinal" => "416" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0260" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "IL8 gene as modifier of cystic fibrosis: unraveling the factors which influence clinical variability" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "L.L. Furlan" 1 => "F.A. Marson" 2 => "J.D. Ribeiro" 3 => "C.S. Bertuzzo" 4 => "J.B. Salomão Junior" 5 => "D.R. Souza" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00439-016-1684-4" "Revista" => array:6 [ "tituloSerie" => "Hum Genet" "fecha" => "2016" "volumen" => "135" "paginaInicial" => "881" "paginaFinal" => "894" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27209008" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0265" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Association of blood eosinophils and plasma periostin with FEV1 response after 3‐month inhaled corticosteroid and long‐acting beta2‐agonist treatment in stable COPD patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H.Y. Park" 1 => "H. Lee" 2 => "W. Koh" 3 => "S. Kim" 4 => "I. Jeong" 5 => "H.K. Koo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Int J Chronic Obstruct Pulm Dis" "fecha" => "2016" "volumen" => "11" "paginaInicial" => "23" "paginaFinal" => "30" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0270" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biomarkers of progression of chronic obstructive pulmonary disease (COPD)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.G. Shaw" 1 => "A. Vaughan" 2 => "A.G. Dent" 3 => "P.E. O’Hare" 4 => "F. Goh" 5 => "R.V. Bowman" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3978/j.issn.2072-1439.2014.11.33" "Revista" => array:6 [ "tituloSerie" => "J Thorac Dis" "fecha" => "2014" "volumen" => "6" "paginaInicial" => "1532" "paginaFinal" => "1547" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25478195" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0275" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of age and sex on response to asthma therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.M. Dunn" 1 => "E. Lehman" 2 => "V.M. Chinchilli" 3 => "R.J. Martin" 4 => "H.A. Boushey" 5 => "E. Israel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201503-0426OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2015" "volumen" => "192" "paginaInicial" => "551" "paginaFinal" => "558" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26068329" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0280" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A genome‐wide association study of bronchodilator response in asthmatics" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Q.L. Duan" 1 => "J. Lasky-Su" 2 => "B.E. Himes" 3 => "W. Qiu" 4 => "A.A. Litonjua" 5 => "A. Damask" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/tpj.2013.5" "Revista" => array:6 [ "tituloSerie" => "Pharmacogenomics J" "fecha" => "2014" "volumen" => "14" "paginaInicial" => "41" "paginaFinal" => "47" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23508266" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0285" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pulmonary function parameters and use of bronchodilators in patients with cystic fibrosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "L.H. Muramatu" 1 => "R. Stirbulov" 2 => "W.C. Forte" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Bras Pneumol" "fecha" => "2013" "volumen" => "39" "paginaInicial" => "48" "paginaFinal" => "55" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23503485" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0290" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Modulation of cystic fibrosis lung disease by variants in interleukin‐8" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.D. Hillian" 1 => "D. Londono" 2 => "J.M. Dunn" 3 => "K.A. Goddard" 4 => "R.G. Pace" 5 => "M.R. Knowles" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/gene.2008.42" "Revista" => array:6 [ "tituloSerie" => "Genes Immun" "fecha" => "2008" "volumen" => "9" "paginaInicial" => "501" "paginaFinal" => "508" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18563170" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0295" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systematic review and meta‐analysis of the association between β2‐adrenoceptor polymorphisms and asthma: a HuGE review" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Thakkinstian" 1 => "M. McEvoy" 2 => "C. Minelli" 3 => "P. Gibson" 4 => "B. Hancox" 5 => "D. Duffy" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Epidemiol" "fecha" => "2005" "volumen" => "162" "paginaInicial" => "201" "paginaFinal" => "211" ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0300" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Influence of genetic variation of the β2‐adrenergic receptor on lung diffusion in patients with cystic fibrosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B.R. Traylor" 1 => "C.M. Wheatley" 2 => "T.T. Skrentny Jr." 3 => "W.T. Foxx-Lupo" 4 => "H. Phan" 5 => "A.E. Patanwala" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.pupt.2011.06.001" "Revista" => array:6 [ "tituloSerie" => "Pulm Pharmacol Ther" "fecha" => "2011" "volumen" => "24" "paginaInicial" => "610" "paginaFinal" => "616" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21703359" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack315684" "titulo" => "Agradecimentos" "texto" => "<p id="par0175" class="elsevierStylePara elsevierViewall">Luciana Montes Rezende, Luciana Cardoso Bonadia e Stephanie Villa‐Nova por seu apoio técnico durante a extração do DNA e na identificação de mutações do gene do <span class="elsevierStyleItalic">RTFC</span>. Marcela Augusta de Souza Pinhel, Michele Lima Gregório, Rafael Fernandes Ferreira, Graciele Domitila Tenani e Heloisa Cristina Caldas por seu apoio técnico na padronização da genotipagem da <span class="elsevierStyleItalic">IL‐8</span>. Maria Ângela Gonçalves de Oliveira Ribeiro por fazer os testes de função pulmonar (LAFIP/Ciped/Unicamp). Rafaella Maionchi Pereira Martins por seu apoio técnico na determinação dos escores clínicos. Maria de Fátima Corrêa Pimenta Servidoni por promover um elo entre ambas as universidades.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "pt" "url" => "/22555536/0000009300000006/v1_201711030110/S2255553617300794/v1_201711030110/pt/main.assets" "Apartado" => array:4 [ "identificador" => "16682" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Artigos originais" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/22555536/0000009300000006/v1_201711030110/S2255553617300794/v1_201711030110/pt/main.pdf?idApp=UINPBA000049&text.app=https://jped.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2255553617300794?idApp=UINPBA000049" ]
Ano/Mês | Html | Total | |
---|---|---|---|
2024 Novembro | 2 | 0 | 2 |
2024 Outubro | 25 | 17 | 42 |
2024 Setembro | 26 | 16 | 42 |
2024 Agosto | 42 | 27 | 69 |
2024 Julho | 26 | 34 | 60 |
2024 Junho | 20 | 13 | 33 |
2024 Maio | 14 | 12 | 26 |
2024 Abril | 16 | 13 | 29 |
2024 Março | 28 | 22 | 50 |
2024 Fevereiro | 24 | 19 | 43 |
2024 Janeiro | 28 | 23 | 51 |
2023 Dezembro | 12 | 19 | 31 |
2023 Novembro | 15 | 23 | 38 |
2023 Outubro | 23 | 29 | 52 |
2023 Setembro | 22 | 29 | 51 |
2023 Agosto | 14 | 17 | 31 |
2023 Julho | 15 | 11 | 26 |
2023 Junho | 13 | 8 | 21 |
2023 Maio | 24 | 15 | 39 |
2023 Abril | 16 | 4 | 20 |
2023 Março | 30 | 16 | 46 |
2023 Fevereiro | 28 | 12 | 40 |
2023 Janeiro | 20 | 17 | 37 |
2022 Dezembro | 40 | 27 | 67 |
2022 Novembro | 29 | 36 | 65 |
2022 Outubro | 37 | 45 | 82 |
2022 Setembro | 20 | 33 | 53 |
2022 Agosto | 27 | 49 | 76 |
2022 Julho | 25 | 48 | 73 |
2022 Junho | 23 | 38 | 61 |
2022 Maio | 30 | 39 | 69 |
2022 Abril | 37 | 40 | 77 |
2022 Março | 30 | 41 | 71 |
2022 Fevereiro | 22 | 33 | 55 |
2022 Janeiro | 12 | 28 | 40 |
2021 Dezembro | 13 | 22 | 35 |
2021 Novembro | 22 | 16 | 38 |
2021 Outubro | 13 | 25 | 38 |
2021 Setembro | 10 | 11 | 21 |
2021 Agosto | 5 | 12 | 17 |
2021 Julho | 3 | 4 | 7 |
2021 Junho | 8 | 11 | 19 |
2021 Maio | 8 | 10 | 18 |
2021 Abril | 15 | 15 | 30 |
2021 Março | 8 | 10 | 18 |
2021 Fevereiro | 7 | 8 | 15 |
2021 Janeiro | 6 | 5 | 11 |
2020 Dezembro | 8 | 8 | 16 |
2020 Novembro | 10 | 14 | 24 |
2020 Outubro | 6 | 5 | 11 |
2020 Setembro | 12 | 16 | 28 |
2020 Agosto | 6 | 10 | 16 |
2020 Julho | 11 | 12 | 23 |
2020 Junho | 2 | 8 | 10 |
2020 Maio | 8 | 16 | 24 |
2020 Abril | 15 | 54 | 69 |
2020 Março | 4 | 16 | 20 |
2020 Fevereiro | 8 | 9 | 17 |
2020 Janeiro | 7 | 11 | 18 |
2019 Dezembro | 8 | 6 | 14 |
2019 Novembro | 12 | 5 | 17 |
2019 Outubro | 11 | 20 | 31 |
2019 Setembro | 9 | 11 | 20 |
2019 Agosto | 12 | 15 | 27 |
2019 Julho | 12 | 8 | 20 |
2019 Junho | 4 | 9 | 13 |
2019 Maio | 5 | 10 | 15 |
2019 Abril | 15 | 8 | 23 |
2019 Março | 8 | 11 | 19 |
2019 Fevereiro | 4 | 5 | 9 |
2019 Janeiro | 5 | 4 | 9 |
2018 Dezembro | 4 | 10 | 14 |
2018 Novembro | 18 | 3 | 21 |
2018 Outubro | 18 | 9 | 27 |
2018 Setembro | 7 | 7 | 14 |
2018 Maio | 5 | 1 | 6 |
2018 Abril | 19 | 2 | 21 |
2018 Março | 20 | 4 | 24 |
2018 Fevereiro | 26 | 4 | 30 |
2018 Janeiro | 30 | 19 | 49 |
2017 Dezembro | 249 | 16 | 265 |
2017 Novembro | 68 | 19 | 87 |
2017 Outubro | 6 | 4 | 10 |
2017 Setembro | 7 | 0 | 7 |